Interspecies Scaling: Predicting Pharmacokinetic Parameters of Antiepileptic Drugs in Humans from Animals with Special Emphasis on Clearance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The objective of this study was to test the interspecies-scaling approach in a series of antiepileptic drugs. Clearance, volume of distribution, and elimination half-life were scaled up from animal data obtained from literature. Four different methods were utilized to generate plots to scale up the clearance values: (i) clearance vs body weight (simple allometric equation); (ii) the product of clearance and maximum life-span potential (MLP) vs body weight (an approach recommended in literature); (iii) the two-term power equation which incorporates both body weight and brain weight suggested by Boxenbaum; and (iv) the product of clearance and brain weight vs body weight (a new approach being introduced in this study). When the predicted values for clearance were qualitatively compared with the observed values in humans, it was found that our proposed method predicted the clearance better than the other three methods. Using the simple allometric equation, the prediction of volume of distribution as a function of body weight was found to be satisfactory. The elimination half-life could not be predicted from simple allometric equations for any of the drugs studied; however, utilizing the equation CL = VK, prediction for half-life was feasible. The results of this study indicate that it is possible to predict reliably the pharmacokinetic parameters of these antiepileptic drugs in humans from animal data using an allometric approach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When MLP and brain weight were incorporated in simple AS, the predicted values showed good agreement with the observation values [89].”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [89]
In the citing paper
“Because of the hybrid nature of the t1/2, this parameter has been poorly estimated by AS [89,114].”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [89]
Citations
Cites
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Man versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 388
Boxenbaum, H. (1980) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065191 · Cited by 347
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 267
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.
Klotz, U., Antonin, K. H., & Bieck, P. R. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30657-9 · Cited by 211
First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives
Boxenbaum, H., & DiLea, C. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04011.x · Cited by 161
Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse.
Löscher, W. (1978) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31137-7 · Cited by 129
(1992) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049209043866 · Cited by 118
Comparative Pharmacokinetics of the Newer Antiepileptic Drugs
Bialer, M. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00002 · Cited by 100
Research works printed but not linked: 5
- Loscher, 1978, J. Pharmacol. Exp. Ther., 204, 255
- Klotz, 1976, J. Pharmacol. Exp. Ther., 199, 67
- EL Sayed, 1978, Arch. Int. Pharma-codyn., 234, 180
- Matsumoto, 1983, Arzneim-Forsch., 33, 961
- Dedrick, 1970, Cancer Chemother. Rep. Part1, 54, 95
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
“a number of modifications were subsequently proposed for improving the accuracy of these predictions [6,7].”
BackgroundThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
“There is an advantage to using the Rule of Exponents with protein-binding correction in many cases.”
MethodInfluentialA Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
“cases these methods give good predictions,[8-10] their The purpose of this work was to propose and physiological basis is questionable and inaccurate evaluate a PBPK strategy for the prediction of results are frequently obtained, particularly when human pharmacokinetics.”
MethodInterspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Self-citationModelling and PBPK Simulation in Drug Discovery
Jones, H. M., Gardner, I. B., & Watson, K. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9088-1 · Cited by 202
“of compounds for animal PK studies and (2) at the clinical candidate selection and “first in human” stages”
InfluentialLave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184
MAHMOOD, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.015 · Cited by 170
Self-citationLav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162
Huang, Q., & Riviere, J. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.934671 · Cited by 149
“In these situations, the prediction of CL can be improved by incorporating the maximum life-span potential (MLP) or BrW of a species (CL MLP = a W or CL BrW = a W) when better scaling cannot be obtained on a log-log scale by using simple allometry, as reported by Mahmood and Balian [18].”
MethodInfluentialA NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
“These modifications include in vitro metabolic data (Lave et al., 1997), correction by either maximum life-span potential (MLP) or brain weight (BrW) (Mahmood and Balian, 1996b), the “rule of exponents” (ROE) (Mahmood and Balian, 1996a), and scaling unbound CL (Feng et al., 2000).”
MethodInfluentialPhysiologically based pharmacokinetics (PBPK)
Espié, P., Tytgat, D., Sargentini-Maier, M.-L., Poggesi, I., & Watelet, J.-B. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891360 · Cited by 136
“This rule provides selection criteria for the use of MLP or BrW, based on the values of the exponents obtained from simple allometry (Mahmood and Balian, 1996b).”
BackgroundMethodInfluentialInterspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species
Tang, H., Hussain, A., Leal, M., Mayersohn, M., & Fluhler, E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016188 · Cited by 150
“The ROE was applied as described by Mahmood and Balian (1996a): 1) if the exponent from SA is between 0.55 and 0.70, SA is applied; 2) if the exponent is between 0.70 and 1.0, the CL MLP correction approach is applied; 3) if the exponent is greater than 1.0, the CL BrW correction approach is…”
BackgroundMethodResultInfluentialPrediction of pharmacokinetic properties using experimental approaches during early drug discovery
Chaturvedi, P. R., Decker, C. J., & Odinecs, A. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00228-3 · Cited by 133
The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Mahmood, I., & Balian, J. D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00001 · Cited by 112
Self-citationHollósy, F., Valko, K. L., Hersey, A., Nunhuck, S., Kéri, G., & Bevan, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050957i · Cited by 113
Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved
Li, R., Barton, H. A., & Varma, M. V. S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0156-z · Cited by 103
“Historically, CLH is predicted from preclinical species using allometric scaling accounting for bodyweight differences across species [48, 49].”
BackgroundNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials
Ozbek, O., Genc, D. E., & Ülgen, K. Ö. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00250 · Cited by 102
“32 The scaling method of rule of exponents (ROE) proposed by Mahmood and Balian in 1996 44 was applied in allometric scaling studies based on nanoparticle pharmacokinetics and resulted in successful outcomes for PEGylated liposomal anticancer drugs.”
Allometric issues in drug development†
Mahmood, I. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9902163 · Cited by 91
Self-citationTang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89
Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling
Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600761662 · Cited by 89
Interspecies scaling of renally secreted drugs
Mahmood, I. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00525-6 · Cited by 88
Self-citationChoi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“Because of the hybrid nature of the t1/2, this parameter has been poorly estimated by AS [89,114].”
BackgroundMethodResultInfluentialFagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 76
“…1992; Hinderling et al 1993; Gascón et al 1994; Jezequel 1994; Cruze et al 1995; Lavé et al 1995a, 1996c, 1997a, 1999a, b; Grene-Lerouge et al 1996; Mahmood & Balian 1996a, b, c, 1999; Obach et al 1997; Sanwald-Ducray & Dow 1997; van Hoogdalem et al 1997; West et al 1997; Chiou et al 1998; Mahmood…”
BackgroundPhysiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans
Luttringer, O., Theil, F., Poulin, P., Schmitt‐Hoffmann, A. H., Guentert, T. W., & Lavé, T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10461 · Cited by 83
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Valic, M. S., & Zheng, G. (2019) · Theranostics · doi:10.7150/thno.34509 · Cited by 65
“Knowing whether and how to apply these corrections appropriately for specific macromolecule drugs and nanomaterials is still unclear, although Mahmood’s ‘rule of exponents’ (ROE) methodology [36, 37] has been successfully applied in published examples of nanomaterial pharmacokinetic allometry.”
BackgroundYamazaki, S., Skaptason, J., Romero, D., Vekich, S., Jones, H. M., Tan, W., Wilner, K. D., & Koudriakova, T. B. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035857 · Cited by 68
“When the rule of exponent (Mahmood and Balian, 1996) was applied, the predicted CLblood was 3.”
MethodInterspecies scaling of biliary excreted drugs
Mahmood, I., & Sahajwalla, C. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10174 · Cited by 62
Self-citationRelationships among liver and kidney volumes, lean body mass and drug clearance
Nawaratne, S., Brien, J.-A. E., Seeman, E., Fabiny, R., Zalcberg, J. R., Cosolo, W., Angus, P., & Morgan, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00812.x · Cited by 66
Mahmood, I. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991773320 · Cited by 59
“The exponent of moxalactam and cefpiramide was less than 0 7, hence according to Mahmood & Balian (1996b) simple allometry should predict the clearance of these two drugs with reasonable accuracy.”
BackgroundMethodSelf-citationDe Buck, S. S., & Mackie, C. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.865 · Cited by 58
“Attempts have been made to improve predictions in these cases by applying correction factors for protein binding, brain weight, maximum lifespan potential and in vitro hepatic CL int data, with varying degree of uccess [105,110,111] .”
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
Zhang, T., Heimbach, T., Lin, W., Zhang, J., & He, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24373 · Cited by 56
Mahmood, I. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06190.x · Cited by 53
Self-citationXiang, H., McSurdy-Freed, J. E., Moorthy, G. S., Hugger, E. D., Bambal, R. B., Han, C., Ferrer, S. B., Gargallo, D. V., & Davis, C. B. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20681 · Cited by 54
Björkman, S., & Redke, F. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774985 · Cited by 52
“The ®rst was the logarithmic form of equation 1: log CL x log BW log a 3 The second equation included brain weight of the animals (Mahmood & Balian 1996a,b): log CL BrW x log BW log a 4 Brain weights of the various species, as percent of body weight, were assumed to be: rats 0 75%, rabbits 0 39%,…”
MethodInfluentialXia, B., Heimbach, T., He, H., & Lin, T. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1821 · Cited by 52
Model-based drug development: application of modeling and simulation in drug development
Kim, T., Shin, S., & Shin, B. S. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0371-3 · Cited by 45
“Despite no physiological significance, the prediction of clearance can be improved by including brain weight or maximum life-span potential terms into the allometric equation for drugs undergoing extensive hepatic metabolism and renal elimination (Mahmood and Balian 1996).”
BackgroundACCURACY OF ALLOMETRICALLY PREDICTED PHARMACOKINETIC PARAMETERS IN HUMANS: ROLE OF SPECIES SELECTION
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004127 · Cited by 46
“…include in vitro correction (Lave et al., 1997), a two-term power function approach (Boxenbaum and Fertig, 1984), maximum life-span potential or brain weight correction (Mahmood and Balian, 1996b), “rule of exponents” (Mahmood and Balian, 1996a), and unbound CL approach (Feng et al., 2000).”
BackgroundNg, C. M., Xiao, Y.-D., Putnam, W. S., Lum, B. L., & Tropsha, A. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20117 · Cited by 42
Sun, W., Liang, Z., & Pei, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.08.001 · Cited by 42
Hayakawa, H., Fukushima, Y., Kato, H., Fukumoto, H., Kadota, T., Yamamoto, H., Kuroiwa, H., Nishigaki, J., & Tsuji, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1409 · Cited by 38
“…characterized by a low or moderate hepatic excretion ratio, physiological correction factors were used to improve the interspecies scaling, such as maximum life span potential (Boxenbaum, 1984), brain weight (Mahmood and Balian, 1996a), and other factors (Lave et al., 1996; Ward et al., 1999).”
MethodResultInterspecies Scaling: Role of Protein Binding in the Prediction of Clearance from Animals to Humans
Mahmood, I. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001214 · Cited by 36
“To improve the predictive performance of an allometric equation, several different approaches have been proposed to predict human clearance such as (1) using species weight and maximum life span potential (MLP),(6) (2) using a two-term power equation based on brain weight and body weight,(7) (3) using the product of C…”
MethodSelf-citationTang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004135 · Cited by 34
“Those values of FMLP and FBrW for some common combinations of animal species are calculated and presented in Table 2.”
BackgroundZaleplon pharmacokinetics and absolute bioavailability
Rosen, A. S., Fournié, P., Darwish, M., Danjou, P., & Troy, S. M. (1999) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199904)20:3<171::aid-bdd169>3.0.co;2-k · Cited by 83
Self-citationInterspecies Scaling: Predicting Oral Clearance in Humans
Mahmood, I. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200201000-00008 · Cited by 33
“70, simple allometry will predict clearance more accurately than CL × MLP or CL × brain weight; (2) if the exponent of the simple allometry lies between 0.”
BackgroundMethodSelf-citationMahmood (2002) · Drug Metabolism and Drug Interactions · doi:10.1515/dmdi.2002.19.1.49 · Cited by 29
First Time in Human for GV196771: Interspecies Scaling Applied on Dose Selection
Iavarone, L., Hoke, J. F., Bottacini, M., Barnaby, R., & Preston, G. C. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008164 · Cited by 28
Mahmood, I. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9702628 · Cited by 27
Self-citationDrug Disposition Viewed in Terms of the Fractal Volume of Distribution
Karalis, V. D., & Macheras, P. E. (2002) · Pharmaceutical Research · doi:10.1023/a:1015378701592 · Cited by 25
Fura, A., Vyas, V. P., Humphreys, W. G., Chimalokonda, A., & Rodrigues, D. (2008) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.632 · Cited by 24
Fractal Volume of Drug Distribution: It Scales Proportionally to Body Mass
Karalis, V. D., Claret, L., Iliadis, A., & Macheras, P. E. (2001) · Pharmaceutical Research · doi:10.1023/a:1010965001162 · Cited by 22
Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling
Kang, H. E., & Lee, M. G. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-1101-4 · Cited by 25
SANWALD-DUCRAY, P., & DOW*, J. (1997) · Xenobiotica · doi:10.1080/004982597240686 · Cited by 19
Liu, D., Song, H., Song, L., Liu, Y., Cao, Y., Jiang, J., & Hu, P. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1205761 · Cited by 19
“Although the concept has been proposed for decades, prediction of human CL based on AS has not been satisfied, even though many modified AS methods were developed to improve predictive accuracy (Mahmood & Balian, 1996; Sharma & McNeill, 2009; Tang & Mayersohn, 2005).”
MethodInfluentialPrediction of Human Clearance Based on Animal Data and Molecular Properties
Huang, W., Geng, L., Deng, R., Lu, S., Ma, G., Yu, J., Zhang, J., Liu, W., Hou, T., & Lü, X. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12567 · Cited by 17
“improved this simple allometry (18): if b is <0.”
BackgroundAmantana, A., Chen, Y., Tyavanagimatt, S., Jones, K. F., Jordan, R., Chinsangaram, J., Bolken, T. C., Leeds, J. M., & Hruby, D. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061514 · Cited by 16
“Based on the ‘‘Rule of Exponents’’ (RoE) [20,22], the Cl/F multiplied by the maximum life span (MLP) correction approach was applied in this study to improve the human Cl/F determination, since the ST-246 Pharmacokinetics and Allometric Scaling”
BackgroundMethodLouis, B., & Agrawal, V. K. (2014) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-014-0166-4 · Cited by 17
“In comparison with the error normally associated with the prediction using interspecies scaling, which is reported to be in the range of 1.56-2.78 (Obach et al., 1997; Mahmood and Balian, 1996), our prediction accuracy is good.”
InfluentialProspective Allometric Scaling: Does the Emperor Have Clothes?
Mahmood, I. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009026 · Cited by 16
Self-citationLiu, D., Ma, X., Liu, Y., Zhou, H., Shi, C., Wu, F. S.-Y., Jiang, J., & Hu, P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.020 · Cited by 16
“exponent method (ROE) ([36]), and hepatic blood flow corrected method (HBF-monkey) were tested.”
MethodInfluentialPavankuamr, V. V., Vinu, C., Mullangi, R., & Srinivas, N. R. (2007) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190987 · Cited by 13
“These included the maximum life span potential (MLP) (21) and brain weight (22).”
BackgroundYang, B., Wu, C., Ji, B., Wu, M., He, Z., Shang, L., & Sun, J. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.03.003 · Cited by 13
“A large number of methodologies including allometric scaling [8-11] and physiologically based pharmacokinetic (PBPK) model [12, 13] have been established for PK prediction.”
MethodMonoclonal Antibodies: Interspecies Scaling With Minimal Preclinical Information
Han, C., & Zhou, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.1 · Cited by 12
Choi, G.-W., Choi, E.-J., Kim, J. H., Kang, D. W., Lee, Y., & Cho, H. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02705-6 · Cited by 12
“However, uncertainty factors exist, such as poor prediction of t1/2 itself (Iftekhar 1996) or limitation in MMPigs study design regarding occurrence of potential interaction between substances since 10 PFASs mixture was administered to MMPigs.”
BackgroundInterspecies scaling: prediction of human biliary clearance and comparison with QSPKR
Morris, M. E., Yang, X., Gandhi, Y., Bhansali, S. G., & Benincosa, L. J. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1761 · Cited by 12
“These methods include corrections using maximum life-span potential (MLP) [6], brain weight (BrW) [7], in vitro metabolic clearance [8], monkey liver blood flow (LBF) method [9], approaches using a two-term power function [10], rule of exponents (ROE) [11] and unbound clearance [12,13].”
MethodMahmood, I. (2001) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2001.18.2.135 · Cited by 10
Self-citationPredicting the Intravenous Pharmacokinetics of Covalent Drugs in Animals and Humans
Stringer, R. A., & Kaster, T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00776 · Cited by 10
Choi, S., Kim, C., Son, H., Hwang, J., & Kang, W. (2020) · Journal of Medicinal Food · doi:10.1089/jmf.2019.4564 · Cited by 14
“14 This study aimed to determine a human dose of fingerroot extracts for use as a health/functional food for alleviation of periodontal inflammation.”
Kumar, V. V. P., & Srinivas, N. R. (2008) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190880 · Cited by 8
“The tool of allometry has been extensively used to gauge and predict the human pharmacokinetic parameters for scores of compounds that represent different therapeutic areas in a retrospective manner (14-20).”
BackgroundMethodHsu, Y., & Linninger, A. A. (2013) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2013.2244893 · Cited by 9
Mahmood, I. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200103000-00005 · Cited by 8
Self-citationAhlawat, P., & Srinivas, N. R. (2008) · Xenobiotica · doi:10.1080/00498250802488577 · Cited by 8
Choi, R., Hulverson, M. A., Schaefer, D. A., Betzer, D. P., Riggs, M. W., Huang, W., Sun, V., Whitman, G. R., McCloskey, M. C., Marsh, K. C., et al. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0013263 · Cited by 7
Comparative Assessment of Empirical and Physiological Approaches on Predicting Human Clearances
Tamaki, S., Komura, H., Kogayu, M., & Yamada, S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22321 · Cited by 9
Lignet, F., Esdar, C., Walter-Bausch, G., Friese‐Hamim, M., Stinchi, S., Drouin, E. E., Bawab, S. E., Becker, A. D., Gimmi, C. D., Sanderson, M. P., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001355 · Cited by 6
“Allometry by rule of exponents as described previously (Mahmood and Balian, 1996), using in vivo M3258 intravenous data from mouse, rat, dog, and monkey and corrected for maximum life span (SAfu/MLP).”
MethodMahmood, I. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122009791 · Cited by 6
Self-citationMorgan, P. (2001) · International Congress Series · doi:10.1016/s0531-5131(01)00282-5 · Cited by 6
“Other correction factors to the simple allometric equation, such as maximum life-span potential, brain weight, protein binding, have been used in prediction of human clearance with success for some compounds [24,28].”
MethodNgo, L. T., Lee, C.-H., Han, N., Back, H., Rhee, S., Noh, K., Yun, H., Kang, W., & Chae, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051862 · Cited by 7
Mullangi, R., Ahlawat, P., Trivedi, R. K., & Srinivas, N. R. (2009) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03191385 · Cited by 5
Critique of Prospective Allometric Scaling: Does the Emperor Have Clothes?
Mahmood, I. (2000) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2000.tb05995.x · Cited by 5
Self-citationPharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator
Østerberg, O., Kiehr, B., Erichsen, L., Poulsen, H. E., & Ingwersen, S. H. (2003) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.344 · Cited by 4
“Correction factors such as brain weight (BrW) and maximum life span potential (MLP) have successfully improved the prediction of human CL for several drugs [4,5].”
BackgroundPrediction of human drug clearance using a single-species, fixed-exponent allometric approach
Hu, T., & Chiu, S. J. (2009) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · Cited by 4
In vitro impacts of glyphosate on manatee lymphocytes
María, M. D., García‐Reyero, N., Stacy, N. I., Abbott, J. R., Yu, F., Pu, R., Kroll, K. J., Barboza, F. R., Walsh, M. T., Perez-Jimenez, J. G., et al. (2024) · Environment International · doi:10.1016/j.envint.2024.109054 · Cited by 3
Liolios, C. C., Xanthopoulos, S., Loudos, G. K., Varvarigou, A. D., & Sivolapenko, G. B. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.07.005 · Cited by 3
Gilibili, R. R., Mullangi, R., & Srinivas, N. R. (2011) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-011-0029-x · Cited by 3
“These included (a) the maximum life span potential (MLP) (Boxenbaum 1982) and brain weight (Mahmood and Balian 1996) (b) two exponential methods applicable to biliary excreted drugs were adopted since ketorolac elimination is also subject to biliary excretion after formation of phase-II metabolites…”
BackgroundMethodInfluentialShaw, J., & Jaw‐Tsai, S. (2010) · Xenobiotica · doi:10.3109/00498254.2010.525261 · Cited by 5
Prediction of Hepatic Clearance in Humans from Experimental Animals and In Vitro Data
Chiba, M., Sugiyama, Y., Ishii, Y., Takahashi, H., & Shibata, Y. (2003) · Informa Healthcare eBooks · doi:10.1201/9781420028485.ch13 · Cited by 4
Cytochrome P450 in Laboratory Animal Species
Spatzenegger, M., Born, S. L., & Halpert, J. R. (2003) · Informa Healthcare eBooks · doi:10.1201/9781420028485.ch6 · Cited by 3
Lavé, T., Luttringer, O., Poulin, P., & Parrott, N. J. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9216-1_5 · Cited by 6
Heimbach, T., Gollen, R., & He, H. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch15 · Cited by 2
Principles, Issues, and Applications of Interspecies Scaling
Mahmood, I. (2004) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203026427.ch7 · Cited by 2
Self-citationNoh, K., & Kang, Ψ. W. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.192 · Cited by 4
Lignet, F., Friese‐Hamim, M., Jaehrling, F., Bawab, S. E., & Rohdich, F. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03611-z · Cited by 2
“F and k a ) via PBPK modeling only, while for the prediction of the terminal arm all methods were [18]; SA, Simple allometry; RoE, Rule of exponents [23]; TME, Tang-Mayersohn-Eq.”
MethodKomura, H., & Iwaki, M. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm062 · Cited by 2
Dedrick, R. L., & Atkinson, A. J. (2007) · Elsevier eBooks · doi:10.1016/b978-012369417-1/50070-5 · Cited by 1
Predicting Human Pharmacokinetics
(2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527645763.ch9 · Cited by 1
Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance
Zhang, D. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/dmnk-6k52 · Cited by 2
Dose Finding in Single Dose Studies by Allometric Scaling
Pähler, T., & Maas, J. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_3
ALLOMETRIC SCALING FOR PREDICTING HUMAN DRUG CLEARANCE
Tang, H. (2005) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Mahmood, I., & Balian, J. D.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Mahmood, Iftekhar
- ORCID
- Mahmood, Iftekhar
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- American Geophysical Union (AGU)
- Published
- 1996-04
- Volume
- 85
- Issue
- 4
- Pages
- 411-414
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2065457233
- Cited by
- 105
- References
- 17
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2020: 3 · 2019: 2 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- interspecies scaling, antiepileptic drugs, pharmacokinetic prediction, drug clearance, allometric scaling, volume of distribution, elimination half-life, brain weight, body weight, animal-to-human extrapolation
- MeSH terms
- Animals, Anticonvulsants, Diazepam, Ethosuximide, Half-Life, Humans, Models, Biological, Species Specificity, Valproic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.